Dr. Wadhwani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
675 N Saint Clair St
Fl 18
Chicago, IL 60611Phone+1 312-695-0596Fax+1 312-695-5232
Summary
- Dr. Shikha Wadhwani is Director of the Glomerular Disease Program at Northwestern University's Feinberg School of Medicine and an Assistant professor in the Division of Nephrology and Hypertension. She is also Program Director for the Glomerular disease fellowship and cofounder of the joint Rheum-Renal Lupus Nephritis clinic at Northwestern. She is committed to providing comprehensive care to patients, and has a clinical interest in glomerulonephritis, vasculitis, and pregnancy-related kidney disease. Her research focuses on clinical outcomes of glomerular diseases in the NIH-funded CureGN cohort. She is site PI/Co-I for clinical trials aimed at investigating novel therapeutics for patients with glomerular disease. She has served on numerous medical advisory boards and spoken in various regional, national, and international forums about lupus nephritis and IgA nephropathy.
Education & Training
- Ohio State University Wexner Medical CenterFellowship in Glomerular Diseases, 2016 - 2017
- Rush University Medical CenterFellowship, Nephrology, 2013 - 2016
- Rush UniversityMS, Clinical Research , 2013 - 2016
- Rush University Medical CenterResidency, Internal Medicine, 2011 - 2013
- Cook County Health and Hospitals SystemInternship, Internal Medicine, 2010 - 2011
- Rush Medical College of Rush University Medical CenterClass of 2010
Certifications & Licensure
- IL State Medical License 2011 - 2026
- OH State Medical License 2016 - 2017
Clinical Trials
- An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis Start of enrollment: 2019 Jul 15
- Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy Start of enrollment: 2018 Sep 05
- Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) Start of enrollment: 2020 Nov 14
- Join now to see all
Publications & Presentations
PubMed
- 80 citationsA Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease.Abhijat Kitchlu, Kenar D. Jhaveri, Shikha Wadhwani, Priya P Deshpande, Ziv Harel
Kidney International Reports. 2021-01-01 - 1 citationsPregnancy History and Kidney Disease Progression Among Women Enrolled in Cure Glomerulonephropathy.Monica L Reynolds, Andrea L Oliverio, Jarcy Zee, Elizabeth M Hendren, Michelle M O'Shaughnessy
Kidney International Reports. 2023-04-01 - 12 citationsKDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases.Laurence H Beck Jr, Isabelle Ayoub, Dawn Caster, Michael J Choi, Jason Cobb
American Journal of Kidney Diseases. 2023-08-01
Professional Memberships
- Member
Other Languages
- Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: